Glaucocalyxin A Derivative Solubility Modification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Glaucocalyxin A has low polarity and poor water solubility, leading to rapid clearance and low bioavailability in vivo, making it unsuitable for direct drug administration, despite its strong anti-autoimmune and anti-tumor effects.
Innovation Solution
A glaucocalyxin A derivative with a dimethylamino or diethylamino group is synthesized, enhancing water solubility and bioavailability, and used in pharmaceutical formulations for autoimmune and cancer treatments, specifically targeting systemic lupus erythematosus, psoriasis, and triple-negative breast cancer.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If glaucocalyxin A is used directly as a drug, then strong anti-autoimmune and anti-tumor effects are achieved in vitro, but poor water solubility and rapid clearance lead to low bioavailability and short half-life in vivo
Solution Approach 1:
The patent modifies the chemical structure of glaucocalyxin A by introducing a dimethylamino group at the C-1 position, changing the chemical parameters of the molecule. This structural modification transforms the compound from poor water solubility to good water solubility, while maintaining the bioactive α,β-unsaturated cyclopentanone group necessary for anti-tumor activity
Solution Approach 2:
The patent creates a derivative compound that combines the core glaucocalyxin A structure with a dimethylamino substituent, forming a composite molecular structure. This composite structure integrates the anti-tumor pharmacophore with a water-solubilizing group, achieving both therapeutic efficacy and improved pharmacokinetic properties
2Reliability
If glaucocalyxin A is administered in large doses to overcome low bioavailability, then some therapeutic effect is achieved, but the treatment time is extended and toxicity risks increase
Solution Approach 1:
By modifying the molecular structure to include a dimethylamino group, the patent changes the pharmacokinetic parameters of the compound, achieving faster absorption and longer half-life. This allows therapeutic effects to be achieved at lower doses with shorter treatment durations compared to the parent compound
3Ease of operation
If the exocylic double bond is structurally modified to improve solubility, then water solubility and bioavailability are enhanced, but the risk of losing the active group α,β-unsaturated cyclopentanone must be avoided
Solution Approach 1:
The patent applies local quality modification by introducing the dimethylamino group specifically at the C-1 position while leaving the critical α,β-unsaturated cyclopentanone group at the C-15 position unchanged. This localized modification improves water solubility without compromising the anti-tumor active site
Solution Approach 2:
The structural modification changes physical parameters (solubility) without altering the chemical parameters of the bioactive group. The dimethylamino substituent modifies molecular polarity and solvation properties while preserving the electrophilic carbonyl group necessary for covalent binding to tumor cell targets
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The derivative exhibits high targetability and oral bioavailability, effectively addressing the limitations of glaucocalyxin A by improving solubility and efficacy in medical treatments for mentioned diseases.
Implementation Method 1
The derivative exhibits high targetability and oral bioavailability, effectively addressing the limitations of glaucocalyxin A by improving solubility and efficacy in medical treatments
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Provided is a glaucocalyxin A derivative, or salt thereof, as represented by the formula (I), a method for preparation of said glaucocalyxin A derivative, and a use for said glaucocalyxin A derivative in preparing pharmaceuticals for fighting autoimmune diseases and tumors, e.g. difficult-to-treat diseases such as systemic lupus erythematosus, psoriasis and triple-negative breast cancer